To support the examination of the criminal justice system's response to HIV nondisclosure by the Department of Justice Canada, 16 we synthesized evidence on the absolute risk of HIV transmission during sex between serodiscordant partners. Our objectives were to determine risk when a sex partner who is HIV-positive (Q1) is taking antiretroviral therapy (with varying levels of viral load); (Q2) is taking antiretroviral therapy and has a suppressed viral load; (Q3) is taking antiretroviral therapy and either partner uses condoms (or other barrier methods); (Q4) is taking antiretroviral therapy and has a suppressed viral load, and either partner uses condoms (or other barrier methods); and when (Q5) either partner uses condoms (or barrier methods) alone.
The Public Health Agency of Canada, in consultation with the Department of Justice Canada, chose these questions and the outcome of interest (absolute risk of HIV transmission) as most relevant to informing public health and legal responses.
Methods
We conducted a systematic review of systematic reviews (overview) and a systematic review of more recent studies that were not available for consideration in previously published reviews (update). Figure 1 presents the analytic framework for the overview and update. We prepared unregistered protocols a priori (Appendices 1 and 2, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.180311/-/DC1; summarized in the following section) by following the criteria from the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P). 17 We followed PRISMA and Cochrane guidance (Supplementary Table S1 , Appendix 3, available at www.cmaj.ca/ lookup/suppl/doi:10.1503/cmaj.180311/-/DC1). 18, 19 
overview review
We developed a comprehensive search strategy (Appendix 1) with assistance from research librarians at Health Canada. We searched MEDLINE, Embase, Global Health and the Cochrane Library from Jan. 1, 2007 , to Mar. 13, 2017 , in addition to review registries (PROSPERO and Cochrane Library) and reference lists.
We included reviews that provided quantitative estimates of absolute risk of sexual transmission of HIV between serodiscordant sex partners (number of HIV transmissions in a given number of sex acts or person-years). Appendix 1 gives the detailed eligibility criteria.
We performed title and abstract screening, full-text screening, data extraction and quality assessments using the A Measurement Tool to Assess Systematic Reviews (AMSTAR) 20 independently and in duplicate, with disagreements resolved by a third reviewer. Our AMSTAR ratings informed the selection of reviews for the update.
update review
We identified 2 high-quality reviews that addressed Q1 to Q4 to update 6, 21 (see Appendix 2, section 3.3). Research librarians at Health Canada helped to develop the search strategy for the update that encompassed any sexual orientation or type of partnership. The strategy was externally peer reviewed using Peer Review of Electronic Search Strategies (PRESS). 22 We searched MEDLINE, Embase, the Cochrane Register of Controlled Trials (CENTRAL) and Web of Science from Nov. 1, 2012, to Apr. 27,
Exposures
Outcome Population Analytic framework illustrating exposure to preventive measures that reduce the risk of transmission between HIV-serodiscordant sex partners. The numbers in the corresponding pathways illustrate the risk of HIV transmission from the HIV-positive partner to the HIV-negative partner during sex for Q1 to Q5. Note: Q1 = to determine risk when a sex partner who is HIV-positive is taking antiretroviral therapy (with varying levels of viral load); Q2 = to determine risk when a sex partner who is HIV-positive is taking antiretroviral therapy and has a suppressed viral load; Q3 = to determine risk when a sex partner who is HIV-positive is taking antiretroviral therapy and either partner uses condoms (or other barrier methods); Q4 = to determine risk when a sex partner who is HIV-positive is taking antiretroviral therapy and has a suppressed viral load, and either partner uses condoms (or other barrier methods); Q5 = to determine risk when either partner uses condoms (or barrier methods) alone.
2017, in addition to trial registries and reference lists. We contacted experts to identify unpublished studies. We did not conduct an update for Q5 because a Cochrane review addressing condom use alone 7 was declared in 2012 to be stable and conclusive evidence not requiring further updates. 7, 23, 24 We included studies that reported or provided data to calculate an absolute risk of sexual transmission of HIV between serodiscordant sex partners. These studies included people living with HIV who were taking antiretroviral therapy with monitoring of their viral load and reported on condom use. We combined the primary studies from the update search with those from the reviews. 6, 21 Appendix 2 gives the detailed eligibility criteria. We performed title and abstract screening, full-text screening, data extraction and study-level risk of bias assessment using the Quality in Prognosis Studies (QUIPS) tool 25 independently and in duplicate, with disagreements resolved by a third reviewer. Our QUIPS ratings informed the risk of bias domain of our overall quality assessments.
We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach for prognostic studies to assess certainty (i.e., confidence or quality) in the evidence as high, moderate, low or very low. [26] [27] [28] For questions with no direct evidence, we used indirect evidence from other questions, populations and sex acts to estimate transmission risk and rated down for indirectness.
statistical analysis
We present descriptive statistics at the study level including aggregate person-years and transmission events. We also describe individual transmission events from all studies in the update. We confirmed that the studies contained independent data. We converted per person-year risk of HIV transmission to incidence per 100 personyears and per-act risk of HIV transmission to incidence per 1000 acts. We calculated incidence of HIV transmission per 100 person-years and exact 95% confidence intervals (CIs) assuming a Poisson distribution. 29 We used SAS for all analyses (SAS Enterprise Guide version 5.1, SAS Institute Inc.). When more than 1 cohort was available, we used the sum of transmission events divided by the sum of personyears to calculate a pooled absolute transmission risk (i.e., incidence) and 95% CIs. We assessed statistical heterogeneity visually with forest plots (because we did not examine comparisons between groups) 30 to inform the "inconsistency" criterion of our GRADE assessment.
categories of transmission risk
To facilitate knowledge translation, we assigned risk categories (no risk, negligible risk, low risk and high risk) to our findings using the criteria outlined in the guideline from the Canadian AIDS Society (Supplementary Table S3 , Appendix 3). 31 We considered 2 criteria when assessing the level of transmission risk associated with an activity: whether there was potential for HIV transmission, and whether there was documented evidence of transmission. 31 
ethics approval
Because we systematically reviewed published studies, no ethics approval was required.
Results
In the overview, of 1414 citations screened, we found 12 systematic reviews [6] [7] [8] 21, [32] [33] [34] [35] [36] [37] [38] [39] that met the eligibility criteria (Supplementary Figure S1 , Appendix 3). Table 1 and Supplementary  Tables S4-S6 (Appendix 3) summarize characteristics of the included reviews and their key findings (Appendix 4, available at www.cmaj .ca/lookup/suppl/doi:10.1503/cmaj.180311/-/DC1 presents full narrative summaries). Our AMSTAR scores ranged from 2 to 9 out of 11 (Supplementary Table S7, Appendix 3).
We updated 2 reviews on use of antiretroviral therapy 6, 21 that included the same 6 studies; 40,44-48 2 of those studies had more recent results identified through our update search. 49, 50 Of 7266 citations screened in our update, 7 met our eligibility criteria. [49] [50] [51] [52] [53] [54] [55] Therefore, 11 studies (4 from the original reviews [44] [45] [46] [47] and 7 from the update search [49] [50] [51] [52] [53] [54] [55] ) met the eligibility criteria (Supplementary Figure S2 , Appendix 3). We identified 13 companion articles (Supplementary Table S20 , Appendix 3). 40, 48, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] We use the terms "male/man," "female/woman" and "heterosexual" according to the language used by the authors as sex, gender and sexual orientation were not otherwise described. We refer to male serodiscordant couples as "gay, bisexual and other men who have sex with men (MSM)" and to female serodiscordant partners as "lesbian, bisexual and other women who have sex with women (WSW)." No reviews or studies reported on barrier methods other than male condoms, specific sex acts other than penile-vaginal or penile-anal, or HIV transmission risk for WSW. We applied indirect evidence from heterosexual sex partners to WSW for Q1 and Q2, which did not involve male condom use. Table 3 lists the risk of HIV transmission for Q1 to Q5. Supplementary Figures S3-S5 (Appendix 3) provide forest plots, and Supplementary Tables S14-S19 (Appendix 3) show the GRADE assessments.
Q1: the hIV-positive sex partner is taking antiretroviral therapy (with varying levels of viral load)
The included studies reported 23 phylogenetically linked HIV transmissions across 10 511 person-years of follow-up on antiretroviral therapy (pooled incidence 0.22 transmissions/100 person-years, 95% CI 0.14-0.33). [44] [45] [46] [47] [49] [50] [51] [52] [53] [54] [55] Among heterosexual sex partners, there were 23 linked transmissions over 9922 person-years (pooled incidence 0.23 transmissions/100 person-years, 95% CI 0.15-0.35). [44] [45] [46] [47] 49, 50, [52] [53] [54] [55] We rated the quality of the evidence as high for heterosexual sex partners and as moderate for WSW because of the application of indirect evidence from heterosexual sex partners. Two studies involving MSM found 0 transmissions over 588.96 personyears (pooled incidence 0.00 transmissions/100 person-years, 95% CI 0.00-0.63). 51, 55 We rated the quality of evidence for MSM as moderate. Based on the criteria from the Canadian AIDS Society, we assigned a low risk of sexual HIV transmission for Q1, because of the potential for transmission during the exchange of bodily fluids, and the small number of reported transmissions in the included studies. Most of the person-years came from cohorts with high levels of adherence to antiretroviral therapy or viral load suppression (Table 2) . Overall condom use varied across studies (Table 2) Table S9 , Appendix 3; Appendix 6). Only 2 studies quantified personyears of follow-up with a viral load of less than 200 copies/mL.
Q2: the hIV-positive sex partner is taking antiretroviral therapy and has a suppressed viral load
Two studies reported transmission risk when an HIV-positive partner was taking antiretroviral therapy with a suppressed viral load of less than 200 copies/mL with measurements taken every 4 to 6 months 66 or at least twice per year. 51 During follow-up, studies of sex acts without the use of condoms reported 0 transmissions over 1327 person-years (pooled incidence 0.00 transmissions/100 personyears, 95% CI 0.00-0.28). 51, 55 Based on high-quality evidence from a single study that included heterosexual sex partners, 0 transmissions occurred over 799 person-years (0.00 transmissions/100 personyears, 95% CI 0.00-0.46). 55 We used this estimate as indirect evidence for WSW and rated it as moderate quality. Based on high-quality evidence from both studies that included MSM, we found 0 transmissions over 527.59 person-years (pooled incidence 0.00 transmissions/ 100 person-years, 95% CI 0.00-0.70). 51, 55 We assigned a negligible risk of sexual HIV transmission for Q2, when an HIV-positive partner is taking antiretroviral therapy and has a suppressed viral load of less than 200 copies/mL on consecutive measurements 4 to 6 months apart, because, despite the potential for transmission during the exchange of bodily fluids, there were no reported transmissions in the included studies under these circumstances. We selected a testing interval of 4 to 6 months given that greater than 90% of the person-years occurred under these conditions.
The same 2 studies 51, 55 reported HIV transmissions per personyears of specific sex acts without condoms, although the followup periods for these acts may not have been mutually exclusive (Supplementary Tables S10, S11 and S14-S19, Appendix 3). In the absence of direct evidence for oral sex, we applied estimates for unspecified heterosexual sex. ‡In this study, the percentage adherence by pill count was determined by comparing the number of pills taken versus the number that should have been taken since ART initiation. 40, 64 §Value calculated by the research team.
Q3: the hIV-positive sex partner is taking antiretroviral therapy (with varying levels of viral load) and either partner uses condoms
No studies reported empirical estimates for Q3; however, a systematic review published in 2014 8 modelled the combined effect of antiretroviral therapy and condoms to derive per-act risks, ranging from 0.003 transmissions per 1000 acts (95% CI 0.00-0.03) for insertive vaginal sex to 0.11 transmissions per 1000 acts (95% CI 0.02-0.73) for receptive anal sex. Furthermore, 4 transmissions were found in 1 study when the HIV-positive partner was taking antiretroviral therapy and reported consistent condom use, 52 although there was inadequate information to calculate an estimate of transmission risk. We assigned a low risk of sexual HIV transmission for penile-vaginal sex and penile-anal sex for Q3 because of the potential for transmission during the exchange of bodily fluids that may occur during a slip, break or other incorrect use of the condom when viral load is not suppressed and the few reports of transmission under these circumstances. Given the paucity of evidence, we did not estimate transmission risk for oral sex when antiretroviral therapy (with variable viral load) and condoms were used together.
Q4: the hIV-positive sex partner is taking antiretroviral therapy and has a suppressed viral load, and either partner uses condoms
No reviews or studies provided direct evidence for Q4. We used indirect evidence from studies that reported on antiretroviral therapy, viral load suppression and sex without the use of condoms to provide a risk estimate (pooled incidence 0.00 transmissions/ 100 person-years, 95% CI 0.00-0.28). 51, 55 We rated the quality of the indirect evidence as moderate for heterosexual sex partners and MSM. We assigned a negligible risk of sexual HIV of hIV transmission among hIV-serodiscordant sex partners when antiretroviral therapy (with or without viral  load suppression) , condoms or both were used transmission for Q4, when an HIV-positive partner is taking antiretroviral therapy, has a suppressed viral load of less than 200 copies/mL on consecutive measurements 4 to 6 months apart and uses condoms, per the rationale for Q2.
Q5: either partner uses condoms alone
Five reviews provided pooled estimates of the risk of HIV transmission 7, 8, 32, 33, 35 when heterosexual sex partners used condoms (Supplementary Tables S4-S6 , Appendix 3). Because the findings of a Cochrane systematic review 7 were less likely to have been confounded by antiretroviral therapy use and were declared as stable conclusive evidence in 2012 by The Cochrane Collaboration, 23, 24 we did not update this review. The authors of the review 7 found that among serodiscordant couples who reported "always" using condoms, there were 1.14 HIV transmissions per 100 person-years (95% CI 0.56-2.04). We assigned a low risk of sexual HIV transmission for Q5 because there is potential for transmission during the exchange of bodily fluids that may occur during a slip, break or other incorrect condom use, and transmissions have occurred among partners reporting consistent condom use.
Interpretation
We found high-quality evidence showing a negligible risk of sexual HIV transmission when an HIV-positive sex partner had a suppressed viral load of less than 200 copies/mL that was maintained through adherence to antiretroviral therapy and confirmed on consecutive measurements every 4 to 6 months. In the GRADE approach, high-quality evidence means we are very confident that the true transmission risk is not higher than the upper limit of the reported confidence interval. We found that the risk of sexual HIV transmission is low when antiretroviral therapy (with varying levels of viral load), condoms or both were used. Based on our findings, relevant case law and other factors, the Department of Justice Canada concluded that the criminal law should not apply to people living with HIV who maintain a suppressed viral load of less than 200 copies/mL. 5 The department also concluded that the criminal law should generally not apply to "persons living with HIV who: are on treatment; are not on treatment but use condoms; or, engage only in oral sex (unless other risk factors are present and the person living with HIV is aware of those risks)." 5 The risk of HIV transmission with varying levels of viral load (Q1) may have been underestimated because most of our analyses were based on cohorts with high levels of adherence to antiretroviral therapy or viral load suppression. There may also have been confounding caused by condom use. For Q2 and Q4, we could not statistically rule out a risk of approximately 27 transmissions in 1000 serodiscordant couples who were followed for 10 years (based on the upper limit of the confidence interval for the estimate); 68 however, a risk this high is unlikely given there were no confirmed transmissions while the viral load was less than 200 copies/mL on consecutive measurements in any study. Where there were 0 transmission events, the upper limits of the 95% CIs were solely a function of the studies' person-years of follow-up. 46, 47, 49, 51, 55 For Q3, the transmission risk a priori should be lower than with either antiretroviral therapy or condom use alone, although it does not meet the criteria from the Canadian AIDS Society for negligible risk. Some practices within a particular Canadian AIDS Society risk category may pose a lower risk than others (e.g., Q3 v. Q5). 69 For Q5, risk of HIV transmission with condom use may have been overestimated (i.e., condom effectiveness is underestimated) because consistent use may have been overreported owing to recall or social desirability bias, confounding by indication (e.g., individuals engaged in higher risk activities more likely to use condoms) and the possible inclusion of nonphylogenetically linked cases in estimates. 7 Our review had a number of strengths including using an equity-based approach in considering all genders, sexual orientations and relationship types in our searches, and developing conclusions for seldom-studied groups including WSW. Our observed transmission rate for Q1 was consistent with that found in a 2013 systematic review 6 (0.14 transmissions/100 personyears, 95% CI 0.04-0.31; Supplementary Table S4, Appendix 3). Unlike previous reviews 6, 21 that relied on modelling and assumptions about eligible person-years of follow-up to develop estimates for Q2, our review relied on empirical data. We also included a rating of certainty in our risk estimates, 28 and assigned levels of risk using a priori objective criteria; 31 both of which may aid the public, as well as the medical and legal communities, in understanding the risks of transmission.
limitations
Our study protocols (Appendices 1 and 2), although developed a priori and peer reviewed, were not registered or published. Our ability to conduct certain analyses (e.g., per-act risk estimates, risk with concomitant sexually transmitted infections or for specific sex acts) was limited by both the level of detail and inconsistent measures across the included studies. Had the data allowed calculation of per-act estimates, however, our conclusions would not have changed. Updates of 2 studies that were included in our review were recently released. 51, 55, 70, 71 If all of the additional follow-up from these studies were eligible for incorporation into our meta-analysis, the upper confidence interval of our estimate for Q2 and Q4 would be lowered (from 0.28 to 0.13), but our point estimate and conclusions would not change. A recent expert consensus has, in any case, cautioned against overreliance on theoretical risks in this context. 72 Finally, the risk of HIV transmission in study populations may not reflect the risks and circumstances in individual relationships.
conclusion
Our findings show that there is a negligible risk of sexually transmitting HIV when an HIV-positive sex partner adheres to antiretroviral therapy and maintains a suppressed viral load of less than 200 copies/mL on consecutive measurements every 4 to 6 months. The risk of sexual HIV transmission is low when an HIVpositive sex partner is taking antiretroviral therapy without a suppressed viral load of less than 200 copies/mL, condoms are used or both. These findings will support individual patient and clinician decision-making, and will have implications for public health case management and contact tracing. The Department of Justice Canada used these findings to inform their 2017 report on the justice system's response to HIV nondisclosure, 5 and they may inform the responses of other justice systems.
